Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAS TIVA trial
KCT0012319Phase 4Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of propofol in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Recurrence-free survival. Started Aug 2024; status: recruiting.
02
Drugs
propofol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0012319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012319.